Strata Critical Medical (SRTA) CAO sells 14,306 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen sold 14,306 shares of Class A common stock on May 11, 2026 in an open-market sale at a weighted average price of $5.79 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following this sale, Cohen directly holds 202,138 shares of the company’s Class A common stock.

Insider Trade Summary 10b5-1

Net Seller: 14,306 shares ($82,832)

Net Sell 1 txn

Insider Cohen Amir

Role Chief Accounting Officer

Sold 14,306 shs ($83K)

Type	Security	Shares	Price	Value
Sale	Class A common stock, $0.0001 par value per share	14,306	$5.79	$83K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 202,138 shares (Direct, null)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.79 to $5.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Key Figures

Shares sold: 14,306 shares Weighted average sale price: $5.79 per share Post-transaction holdings: 202,138 shares +1 more

4 metrics

Shares sold 14,306 shares Open-market sale on May 11, 2026

Weighted average sale price $5.79 per share Class A common stock sale

Post-transaction holdings 202,138 shares Direct ownership after May 11, 2026 sale

Net buy/sell shares -14,306 shares TransactionSummary net-sell direction

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Class A common stock

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A common stock financial

"Class A common stock, $0.0001 par value per share"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 04:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Amir

(Last)

(First)

(Middle)

C/O STRATA CRITICAL MEDICAL, INC.

666 THIRD AVENUE, 25TH FLOOR

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock, $0.0001 par value per share	05/11/2026		S⁽¹⁾		14,306	D	$5.79⁽²⁾	202,138	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.79 to $5.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Remarks:

	/s/ Melissa M. Tomkiel, Attorney-in-fact for Amir Cohen	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did SRTA’s Amir Cohen report on this Form 4?

Amir Cohen reported selling 14,306 shares of Strata Critical Medical Class A common stock. The sale occurred on May 11, 2026 as an open-market transaction at a weighted average price of $5.79 per share, according to the Form 4 details.

At what price did SRTA’s Chief Accounting Officer sell his shares?

The reported price was a weighted average of $5.79 per share. Footnotes explain the 14,306 shares were sold in multiple trades at prices ranging from $5.79 to $5.81, and detailed trade breakdowns are available on request from the reporting person.

How many SRTA shares does Amir Cohen hold after the reported sale?

After the reported sale, Amir Cohen directly holds 202,138 shares of Strata Critical Medical Class A common stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects his remaining direct position following the May 11, 2026 transactions.

Was the SRTA insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025. Such plans pre-arrange trades, reducing the significance of short-term timing decisions for this particular insider sale.

What type of security did SRTA’s insider sell in this transaction?

The insider sold Strata Critical Medical’s Class A common stock with a par value of $0.0001 per share. The Form 4 classifies the transaction as involving non-derivative securities, meaning it related to actual shares rather than options or other derivative instruments.

How many shares in total did SRTA’s insider sell in this Form 4?

The Form 4 shows a total sale of 14,306 shares of Class A common stock. The transaction summary identifies one sell transaction and reports 14,306 sell shares, with a net buy/sell direction described as net-sell for this insider activity on May 11, 2026.